Adaptimmune Therapeutics PLC — Director's Dealing 2018

Sep 1, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2018-08-29

Reporting Person: Binder-Scholl Gwendolyn Knowlton (Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-29	American Depositary Shares	S	25000	$10.25	Disposed	0	Direct

Footnotes

F1: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ordinary shares were obtained from the exercise of share options granted on March 20, 2015. The exercise of share options and the sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2018.

F2: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $10.15 to $10.41, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.